Tumor microenvironmental studies revealed that tumor-associated acidosis abrogated the ability of dual nivolumab-ipilimumab to enhance IFN-γ production in OAC donor PBMCs ex vivo (16). This evidence concerns the gene IFNG and neoplasm.